Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec has entered into a research collaboration and license agreement with Novartis. Both firms will partner to discover and develop novel treatments for hearing loss and balance disorders.
Subscribe to our email newsletter
Preclinical results suggest that delivery of the atonal gene using GenVec’s innovative adenovector technology may have the potential to restore hearing and balance function.
As per the agreement, GenVec is licensing the world-wide rights to its preclinical hearing loss and balance disorders program to Novartis. GenVec will receive a $5m upfront payment and Novartis has purchased $2m in GenVec common stock.
In addition, GenVec will receive funding from Novartis for a research program focused on developing additional adenovectors for hearing loss. If certain clinical, regulatory and sales milestones are met, GenVec is eligible to receive up to $213.6m, including upfront and milestone payments, in addition to royalties on future sales.
Paul Fischer, president and chief executive officer of GenVec, said: “Our technology has great promise and this collaboration provides an excellent mechanism to move the development of new treatments forward. We believe Novartis is an ideal collaborator for GenVec. They have the experience, expertise, and resources to develop and commercialize innovative products on a world-wide basis.”